WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE) (the "Company", "Kane" or "Kane Biotech") announces that today it has completed its previously announced non-brokered private placement offering (the "Offering") of common shares of the Company ("Shares").At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 to an insider of the Company.The net proceeds of the Offering will be used for working capital and ge ...

Core Points - Kane Biotech Inc. has completed a non-brokered private placement offering of common shares, issuing 14,000,000 shares at a price of $0.05 per share, resulting in gross proceeds of $700,000 [2] - The net proceeds from the offering will be allocated for working capital and general corporate purposes [2] - The transaction is classified as a "related party transaction" under Multilateral Instrument 61-101, and the company is exempt from formal valuation and minority approval requirements [3] Company Overview - Kane Biotech is focused on developing innovative wound care treatments that target biofilms, which contribute to antibiotic resistance in wounds, leading to serious clinical outcomes and high costs [5] - The company's products, including revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray, have received US FDA 510(k) clearance and Health Canada approval [5]